Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Fosun Pharma and Arcera Life Sciences Forge Strategic Partnership to Bridge Chinese Biotech Innovation with Global Markets

Fineline Cube Apr 29, 2026
Company Deals

Hengrui Pharmaceuticals Partners with Sun Yat-sen University to Integrate Industry-Academia Innovation Ecosystem

Fineline Cube Apr 29, 2026
Company Deals

Vivacta Biotechnology Secures $50M+ Series A Financing to Advance In Vivo CAR-T Therapy GT801

Fineline Cube Apr 29, 2026
Company Deals

Thermo Fisher Scientific to Divest Microbiology Business to Astorg for $1.075 Billion – Strategic Portfolio Optimization

Fineline Cube Apr 28, 2026
Company Deals

Aureka Biotechnologies Secures $35M Series A+ Financing to Advance AuraIDE Platform for Functional Antibody Design

Fineline Cube Apr 28, 2026
Policy / Regulatory

NMPA Tightens Post-Marketing Requirements for Conditionally Approved Drugs in China, Mandating Four-Year Confirmatory Studies and Annual Progress Reporting

Fineline Cube Apr 27, 2026
Company Drug

HutchMed’s Sovleplenib Granted NMPA Priority Review for Warm Antibody Autoimmune Hemolytic Anemia

Fineline Cube Apr 30, 2026
Company Drug

Changchun High & New Tech’s GenSci161 Bispecific Antibody Receives NMPA Approval for Non-Infectious Uveitis Trial

Fineline Cube Apr 29, 2026
Company

Takeda’s Strategic Shift: China Becomes Integral to Global R&D Pipeline

Fineline Cube Apr 3, 2024

Japan’s Takeda Pharmaceuticals (NYSE: TAK) has underscored its commitment to the Chinese market at this...

Company Drug

Zai Lab Announces Positive Phase III Data for Krazati in KRASG12C-mutated NSCLC, Plans NDA Filing in China

Fineline Cube Apr 2, 2024

Zai Lab (NASDAQ: ZLAB; HKG: 9688), a China-based biotech company, has announced positive Phase III...

Company Drug

Alexion’s Voydeya Earns FDA Nod as Add-on Therapy for PNH-Associated Extravascular Hemolysis

Fineline Cube Apr 2, 2024

Alexion, the rare disease unit of AstraZeneca (AZ; NASDAQ: AZN) based in the UK, has...

Company Drug

Viatris Launches Ryzumvi in the US for Rapid Reversal of Pharmacologically-Induced Pupil Dilation

Fineline Cube Apr 2, 2024

Viatris Inc. (NASDAQ: VTRS) has launched its alpha-adrenergic blocker Ryzumvi (phentolamine) in the US market,...

Company Medical Device

Huihe Healthcare’s Vispearl Microsphere Earns Marketing Approval in China for Innovative Cancer Treatment

Fineline Cube Apr 2, 2024

Shanghai-based Huihe Healthcare, a developer of interventional medical devices for structural heart diseases, has secured...

Company Drug

J&J’s Nipocalimab Fast-Tracked by FDA for Reducing FNAIT Risk in Pregnant Adults

Fineline Cube Apr 2, 2024

The US Food and Drug Administration (FDA) has accepted Johnson & Johnson’s (J&J; NYSE: JNJ)...

Company Policy / Regulatory

US Lawmakers Expand Scrutiny on Chinese Biotech Firms with Potential Military Ties

Fineline Cube Apr 2, 2024

Despite his announced retirement from Congress effective April 19 this year, Mike Gallagher continues to...

Company

Lepu Biotechnology Reports 1,347% YOY Revenue Increase in 2023 Financial Results

Fineline Cube Apr 2, 2024

Lepu Biotechnology Co., Ltd (HKG: 2157), a biopharmaceutical company based in China, has released its...

Company Deals

Legend Biotech and Janssen Pharmaceutical Expand Partnership with Novartis for Carvykti Production

Fineline Cube Apr 2, 2024

Legend Biotech Corporation (NASDAQ: LEGN), a leading Chinese biotech firm, and its U.S. partner Janssen...

Company

Danaher Corporation Partners with Chongqing Liang Jiang New Area to Establish Western Innovation Center

Fineline Cube Apr 2, 2024

Danaher Corporation (NYSE: DHR), a leading science and technology services provider in the U.S., has...

Company Deals

China Medical System Expands Portfolio with Incyte’s Povorcitinib for Autoimmune Diseases

Fineline Cube Apr 2, 2024

China Medical System Holdings (CMS; HKG: 0867) has announced a new cooperation and licensing agreement...

Company Drug

Shanghai Fosun Pharma and Meiji Seika Pharma Launch Phase III Studies for Anti-Infective Nacubactam

Fineline Cube Apr 2, 2024

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196), a leading pharmaceutical company based...

Company Medical Device

Johnson & Johnson MedTech Launches CPX4 PLUS Tissue Expander for Breast Reconstruction in China

Fineline Cube Apr 2, 2024

Johnson & Johnson (J&J, NYSE: JNJ) MedTech, a leading healthcare conglomerate in the US, has...

Company Deals

ETERN Therapeutics Secures Funding to Advance LLPS Platform and Clinical Trials for Anti-Tumor Drugs

Fineline Cube Apr 2, 2024

ETERN Therapeutics, a Shanghai-based developer of small-molecule anti-tumor drugs, has announced the commencement of a...

Company Drug

Junshi Biosciences Gets Green Light for Global Phase III Study of Tifcemalimab Combination Therapy in LS-SCLC

Fineline Cube Apr 2, 2024

Shanghai Junshi Biosciences Co., Ltd (HKG: 1877), a leading biotech company based in China, has...

Policy / Regulatory

China’s National Joint Procurement Office Unveils Renewed Insulin Procurement Contracts

Fineline Cube Apr 1, 2024

The National Joint Procurement Office in China announced the upcoming renewal of drug procurement contracts...

Company Drug

FDA Reviews Eisai’s Monthly Maintenance Therapy for Early Alzheimer’s with Leqembi

Fineline Cube Apr 1, 2024

Last week, the US Food and Drug Administration (FDA) announced the acceptance of an indication...

Company Drug

Bristol Myers Squibb’s Krazati Trial Yields Positive Phase III Results in NSCLC

Fineline Cube Apr 1, 2024

Last week, Bristol Myers Squibb (BMS; NYSE: BMY) unveiled preliminary results from a Phase III...

Medical Device R&D

Chinese Scientists Discover Breakthrough Biodegradable Piezoelectric Material for Medical Implants

Fineline Cube Apr 1, 2024

A team of Chinese scientists from Southeast University in Nanjing has made significant strides in...

Company Drug Legal / IP R&D

China’s CNIPA Upholds Patent for Nobel-Winning CRISPR/Cas9 Gene Editing Technology

Fineline Cube Apr 1, 2024

The China National Intellectual Property Administration (CNIPA) has upheld a key patent surrounding the CRISPR/Cas9...

Posts pagination

1 … 373 374 375 … 659

Recent updates

  • Suzhou Basecare Medical Secures China’s First NMPA Approval for Thalassemia Preimplantation Genetic Testing Kit
  • HutchMed’s Sovleplenib Granted NMPA Priority Review for Warm Antibody Autoimmune Hemolytic Anemia
  • Novartis Q1 2026 Results Show Strong Brand Momentum Offset by Generic Erosion; FY Guidance Reaffirmed
  • Astellas Reports Strong FY2025 Results with 12% Revenue Growth Driven by Oncology Portfolio Expansion
  • Fosun Pharma Reports Strong Q1 2026 Results with 22% Profit Growth and Robust Pipeline Advancement
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Medical Device

Suzhou Basecare Medical Secures China’s First NMPA Approval for Thalassemia Preimplantation Genetic Testing Kit

Company Drug

HutchMed’s Sovleplenib Granted NMPA Priority Review for Warm Antibody Autoimmune Hemolytic Anemia

Company

Novartis Q1 2026 Results Show Strong Brand Momentum Offset by Generic Erosion; FY Guidance Reaffirmed

Company

Astellas Reports Strong FY2025 Results with 12% Revenue Growth Driven by Oncology Portfolio Expansion

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.